or unexplained chronic cough (UCC) in adults. Per the CRL, the FDA concluded that the data supported by Merck for gefapixant did not provide sufficient evidence to prove its clinical benefit in ...

It has been estimated that chronic cough affects up to 10% of the US population, with one in five of them getting no benefit from current treatments such as opioids and corticosteroids.

Merck (NYSE:MRK) shares were flat on Monday after a group of independent advisors to the FDA voted against the company's P2X3 receptor antagonist, gefapixant, designed as a chronic cough therapy ...

Merck filed for approval of gefapixant in March 2021 on the strength of a pair of phase 3 trials – COUGH-1 and COUGH-2 – which found that the drug reduced 24-hour cough frequency by 18% and 15 ...

Chronic cough is a symptom, a condition that can have ... This research was supported by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. In addition to his role as a research ...

Findings of a systematic review highlight the need for standardized assessment tools and targeted treatments for chronic ...

Background: Children presenting with chronic cough are common to the primary care physicians, but data on the etiology are scant. Methods: We evaluated 40 children (age range, 5 to 12 years ...

Gefapixant decreased cough-induced stress urinary incontinence (CSUI) episodes in women with refractory/unexplained chronic cough and CSUI.

In a recent study published in ERJ Open Research, researchers investigated the heritability of chronic cough, considering different types of cough (productive vs. nonproductive). Their findings ...

Chronic cough is among the most common reasons for seeking medical care, with middle-aged women the group most affected. New studies at Uppsala University also show that this condition appears to ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types of gynecologic cancers. The FDA approves MRK's Keytruda for first-line ...